Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BCL3 | P20749 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3232291 | 0.92 | EPHX2 (0.47) | NAMPTEPHX2CD274CASRSMN1; SMN2 | |
| SCHEMBL3230756 | 0.90 | EPHX2 (0.46) | NAMPTEPHX2CD274CASRSMN1; SMN2 | |
| SCHEMBL2477762 | 0.87 | CD274 (0.45) | EPHX2CD274CASRPOLBRAB9A | |
| SCHEMBL3832733 | 0.87 | EPHX2 (0.48) | NAMPTEPHX2CASRSMN1; SMN2PIK3CA | |
| SCHEMBL2474155 | 0.86 | CD274 (0.42) | NAMPTEPHX2CD274CASRPOLB | |
| SCHEMBL2477400 | 0.85 | CYP2D6 (0.48) | CD274CASRSMN1; SMN2LMNAPOLB | |
| SCHEMBL2477555 | 0.85 | CD274 (0.47) | EPHX2CD274LMNAALDH1A1GAA | |
| SCHEMBL2475610 | 0.84 | NAMPT (0.52) | NAMPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4219747 | 0.84 | CD274 (0.41) | EPHX2CD274LMNAPOLBMTOR | |
| SCHEMBL10476433 | 0.83 | CD274 (0.46) | EPHX2CD274POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-2107052-B1 | NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2107052-A1 | NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | NAMPT 3896/4885EPHX2 3775/4885CD274 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.